Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study

Conclusions Vorolanib can safely be combined with everolimus. Encouraging activity is seen in RCC and NET. Further studies are warranted.Trial Registration Number: NCT01784861.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research